Erianin

Name: Erianin
Brand: MedChemExpress
SKU: HY-N0517
Rating: 5.0 (11 reviews)

Cat. No.: HY-N0517 Purity: 99.62%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Erianin, often used as an antipyretic and analgesic agent, could inhibit IDO-induced tumor angiogenesis.

For research use only. We do not sell to patients.

CAS No. : 95041-90-0

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	Get quote
200 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 11 publication(s) in Google Scholar

Other Forms of Erianin:

Erianin (Standard) Get quote

11 Publications Citing Use of MCE Erianin

Cell Proliferation/Viability Assay

: Erianin purchased from MedChemExpress. Usage Cited in: Nutr Cancer. 2023;75(6):1473-1484. [Abstract]; Erianin (15, 30, 60, 120, 240 nM; 48 h) suppresses the viability of various ESCC cells in a dose-dependent manner, especially the TE-10 and KYSE-150 cells.(TE-1, KYSE-30, KYSE-410, KYSE-150, and TE-10 cells belong to ESCC cells)

: Erianin purchased from MedChemExpress. Usage Cited in: Nutr Cancer. 2023;75(6):1473-1484. [Abstract]; Erianin (120 nM; 24 h) significantly inhibits the proliferation of TE-10 and KYSE-150 cells.

: Erianin purchased from MedChemExpress. Usage Cited in: Nutr Cancer. 2023;75(6):1473-1484. [Abstract]; Erianin (120 nM; 24 h) significantly inhibits the expression of vimentin, N-cadherin and β-catenin and increases the expression of E-cadherin in TE-10 and KYSE-150 cells.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Erianin, often used as an antipyretic and analgesic agent, could inhibit IDO-induced tumor angiogenesis.

Cellular Effect

Cell Line	Type	Value	Description	References
143B	IC₅₀	26.8 nM Compound: Erianin	Antiproliferative activity against human 143B cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human 143B cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 37804769]
143B	IC₅₀	41 nM Compound: Erianin	Antiproliferative activity against human 143B cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human 143B cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 37804769]
143B	IC₅₀	58.2 nM Compound: Erianin	Antiproliferative activity against human 143B cells assessed as inhibition of cell growth measured after 24 hrs by MTT assay Antiproliferative activity against human 143B cells assessed as inhibition of cell growth measured after 24 hrs by MTT assay	[PMID: 37804769]
A-375	IC₅₀	20.6 nM Compound: Erianin	Antiproliferative activity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 37804769]
A549	ED₅₀	0.01 μM Compound: 1c	Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines	[PMID: 1875350]
A549	IC₅₀	0.6 nM Compound: Erianin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37804769]
A549	IC₅₀	70 nM Compound: Erianin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 37804769]
Bel-7402	IC₅₀	21.5 nM Compound: Erianin	Antiproliferative activity against human Bel-7402 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human Bel-7402 cells incubated for 72 hrs by MTT assay	[PMID: 37804769]
EJM	IC₅₀	65 nM Compound: Erianin	Antitumor activity against human EJM cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antitumor activity against human EJM cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 37804769]
HCC 2998	IC₅₀	70 nM Compound: Erianin	Antiproliferative activity against human HCC 2998 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HCC 2998 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 37804769]
HCCLM3	IC₅₀	17.68 nM Compound: Erianin	Antiproliferative activity against human HCCLM3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human HCCLM3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 34931827]
HCT-116	IC₅₀	60 nM Compound: Erianin	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 37804769]
HL-60	IC₅₀	0.05 μM Compound: 24	Cytotoxicity of compound against HL-60 human leukemia cells Cytotoxicity of compound against HL-60 human leukemia cells	[PMID: 1552500]
HL-60	IC₅₀	38 nM Compound: Erianin	Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 37804769]
HL-60	IC₅₀	40 nM Compound: Erianin	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37804769]
HLE	IC₅₀	28.6 nM Compound: Erianin	Antiproliferative activity against human HLE cells Antiproliferative activity against human HLE cells	[PMID: 37804769]
HT-29	ED₅₀	0.081 μM Compound: 1c	Cytotoxic concentration required to inhibit 50% cell growth in HT-29 colon adenocarcinoma cell lines Cytotoxic concentration required to inhibit 50% cell growth in HT-29 colon adenocarcinoma cell lines	[PMID: 1875350]
HeLa	IC₅₀	0.22 μM Compound: Erianin	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability by MTT assay	[PMID: 37804769]
HeLa	IC₅₀	8300 nM Compound: Erianin	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37804769]
HepG2	IC₅₀	119.6 nM Compound: Erianin	Anticancer activity against human HepG2 cells assessed as cell growth reduction incubated for 48 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as cell growth reduction incubated for 48 hrs by MTT assay	[PMID: 37804769]
HepG2	IC₅₀	128.2 nM Compound: Erianin	Anticancer activity against human HepG2 cells assessed as cell growth reduction incubated for 24 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as cell growth reduction incubated for 24 hrs by MTT assay	[PMID: 37804769]
HepG2	IC₅₀	174.8 nM Compound: Erianin	Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth	[PMID: 37804769]
HepG2	IC₅₀	43.7 nM Compound: Erianin	Anticancer activity against human HepG2 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay	[PMID: 37804769]
HepG2	IC₅₀	583.7 nM Compound: Erianin	Antiproliferative activity against human HepG2 cells Antiproliferative activity against human HepG2 cells	[PMID: 37804769]
HepG2	IC₅₀	72.8 nM Compound: Erianin	Anticancer activity against human HepG2 cells assessed as reduction in cell viability Anticancer activity against human HepG2 cells assessed as reduction in cell viability	[PMID: 37804769]
HepG2	IC₅₀	99.26 nM Compound: Erianin	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 34931827]
Huh-7	IC₅₀	44.3 nM Compound: Erianin	Antiproliferative activity against human Huh-7 cells Antiproliferative activity against human Huh-7 cells	[PMID: 37804769]
Ishikawa	IC₅₀	40.6 nM Compound: Erianin	Antiproliferative activity against human Ishikawa cells assessed as reduction in cell viability by MTS assay Antiproliferative activity against human Ishikawa cells assessed as reduction in cell viability by MTS assay	[PMID: 37804769]
L1210	IC₅₀	0.07 μM Compound: 24	Compound was tested for the inhibition of L1210 leukemia cells growth in mice Compound was tested for the inhibition of L1210 leukemia cells growth in mice	[PMID: 1552500]
LLC-MK2	IC₅₀	2.3 nM Compound: Erianin	Antiproliferative activity against Rhesus monkey LLC-MK2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against Rhesus monkey LLC-MK2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37804769]
LNCaP	IC₅₀	26.2 nM Compound: Erianin	Cytotoxicity against human LNCaP cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human LNCaP cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 37804769]
LNCaP	IC₅₀	26.5 nM Compound: Erianin	Cytotoxicity against human LNCaP cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human LNCaP cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 37804769]
LNCaP	IC₅₀	33.8 nM Compound: Erianin	Cytotoxicity against human LNCaP cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay Cytotoxicity against human LNCaP cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay	[PMID: 37804769]
MCF7	ED₅₀	0.33 μM Compound: 1c	Cytotoxic concentration required to inhibit 50% cell growth in MCF-7 breast carcinoma cell lines Cytotoxic concentration required to inhibit 50% cell growth in MCF-7 breast carcinoma cell lines	[PMID: 1875350]
MCF7	IC₅₀	13 nM Compound: Table 1, R4C1	Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 19135763]
MCF7	IC₅₀	60 nM Compound: Erianin	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 37804769]
MDA-MB-231	IC₅₀	71 nM Compound: Erianin	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 37804769]
MDA-MB-468	IC₅₀	40 nM Compound: Erianin	Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 37804769]
MHCC97	IC₅₀	386.4 nM Compound: Erianin	Antiproliferative activity against human MHCC97 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human MHCC97 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 34931827]
MIA PaCa-2	IC₅₀	50 nM Compound: Erianin	Antiproliferative activity against human MIA PaCa-2 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MIA PaCa-2 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 37804769]
MLM	ED₅₀	0.01 μM Compound: 1c	Cytotoxic concentration required to inhibit 50% cell growth in MLM melanoma cell lines Cytotoxic concentration required to inhibit 50% cell growth in MLM melanoma cell lines	[PMID: 1875350]
NCI-H1975	IC₅₀	0.5 nM Compound: Erianin	Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37804769]
P388	IC₅₀	0.11 μM Compound: 1d	Concentration required for 50% inhibition of P388 murine leukemia cell growth in MTT assay Concentration required for 50% inhibition of P388 murine leukemia cell growth in MTT assay	[PMID: 11140732]
PC-3	IC₅₀	26 nM Compound: Erianin	Antiproliferative activity against human PC-3 cells assessed as reduction of cell viability incubated for 24 to 72 hrs by CCK-8 assay Antiproliferative activity against human PC-3 cells assessed as reduction of cell viability incubated for 24 to 72 hrs by CCK-8 assay	[PMID: 37804769]
PLC-PRF-5	IC₅₀	55 nM Compound: Erianin	Antiproliferative activity against human PLC-PRF-5 cells Antiproliferative activity against human PLC-PRF-5 cells	[PMID: 37804769]
SK-HEP1	IC₅₀	757.1 nM Compound: Erianin	Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 34931827]
SK-MEL-5	ED₅₀	0.0021 μM Compound: 1c	Cytotoxic concentration required to inhibit 50% cell growth in SKMEL-5 melanoma cell lines Cytotoxic concentration required to inhibit 50% cell growth in SKMEL-5 melanoma cell lines	[PMID: 1875350]
SK-MEL3	IC₅₀	12 nM Compound: Erianin	Antiproliferative activity against human SK-MEL3 cells harboring BRAF V600E mutant assessed as reduction in cell viability by cell-titer Glo assay Antiproliferative activity against human SK-MEL3 cells harboring BRAF V600E mutant assessed as reduction in cell viability by cell-titer Glo assay	[PMID: 37804769]
SMMC-7721	IC₅₀	81 nM Compound: Erianin	Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 37804769]
SNU-449	IC₅₀	236.3 nM Compound: Erianin	Antiproliferative activity against human SNU-449 cells Antiproliferative activity against human SNU-449 cells	[PMID: 37804769]
T-24	IC₅₀	0.46 μM Compound: 33	Anti-cancer activity against human T24 cells Anti-cancer activity against human T24 cells	[PMID: 32711292]
T-24	IC₅₀	45.9 nM Compound: Erianin	Antiproliferative activity against human T24 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human T24 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37804769]

In Vitro

Erianin is often used as antipyretic and analgesic agent. Erianin belongs to bibenzyl derivatives in structure, with the activity of anti-virus, anti-bacterial, as well as anti-benign prostatic hyperplasia. Erianin has obvious damage on 2LL-IDO cells, Erianin basically has no cytotoxicity on human normal liver cell line L02, and cell viability is maintained at around 85%^[1]. Erianin inhibits the growth of HeLa cells and induces apoptosis in a dose and time dependent manner, inducing cell cycle arrest at the G2/M stage. Erianin treatment also increases the expression of Bax and caspase 3, but decreases levels of Bcl 2 and phosphorylated ERK1/2^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

318.36

Formula

C₁₈H₂₂O₅

CAS No.

95041-90-0

Appearance

Solid

Color

White to off-white

SMILES

OC1=CC(CCC2=CC(OC)=C(OC)C(OC)=C2)=CC=C1OC

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (314.11 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.1411 mL	15.7055 mL	31.4110 mL
5 mM	0.6282 mL	3.1411 mL	6.2822 mL
10 mM	0.3141 mL	1.5705 mL	3.1411 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Saline
Solubility: 5 mg/mL (15.71 mM); Suspended solution; Need ultrasonic
Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.53 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.53 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 4

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (6.53 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 25 mg/mL (78.53 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.77%

Select Batch:

Data Sheet (273 KB) SDS (394 KB)

COA (247 KB) HNMR (128 KB) RP-HPLC (259 KB) MS (70 KB)

Handling Instructions (2659 KB)

References

[1]. Su C, et al. Erianin inhibits indoleamine 2, 3-dioxygenase -induced tumor angiogenesis. Biomed Pharmacother. 2017 Apr;88:521-528. [Content Brief]

[2]. Li M, et al. Erianin inhibits human cervical cancer cell through regulation of tumor protein p53 via the extracellular signal-regulated kinase signaling pathway. Oncol Lett. 2018 Oct;16(4):5006-5012. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.1411 mL	15.7055 mL	31.4110 mL	78.5275 mL
	5 mM	0.6282 mL	3.1411 mL	6.2822 mL	15.7055 mL
	10 mM	0.3141 mL	1.5705 mL	3.1411 mL	7.8527 mL
	15 mM	0.2094 mL	1.0470 mL	2.0941 mL	5.2352 mL
	20 mM	0.1571 mL	0.7853 mL	1.5705 mL	3.9264 mL
	25 mM	0.1256 mL	0.6282 mL	1.2564 mL	3.1411 mL
	30 mM	0.1047 mL	0.5235 mL	1.0470 mL	2.6176 mL
	40 mM	0.0785 mL	0.3926 mL	0.7853 mL	1.9632 mL
	50 mM	0.0628 mL	0.3141 mL	0.6282 mL	1.5705 mL
	60 mM	0.0524 mL	0.2618 mL	0.5235 mL	1.3088 mL
	80 mM	0.0393 mL	0.1963 mL	0.3926 mL	0.9816 mL
	100 mM	0.0314 mL	0.1571 mL	0.3141 mL	0.7853 mL

Erianin Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Erianin95041-90-0BacterialInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Erianin

Customer Review

Other Forms of Erianin:

Erianin Related Antibodies

11 Publications Citing Use of MCE Erianin

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Erianin Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Erianin Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report